{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:01:30Z","timestamp":1789052490695,"version":"build-2803163510"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review summarizes the most recent approaches in managing cutaneous involvement, one of the main clinical manifestations of systemic sclerosis (SSc). The following article is written for clinicians and researchers looking for optimizing patient care and exploring new therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent studies have shown advancements in the management of cutaneous manifestations of SSc. While mycophenolate remains the first-line treatment, other immunosuppressive therapies targeting different pathways have shown promising results. B-cell depleting agents, such as Rituximab (RTX), are being increasingly utilized for cutaneous scleroderma with positive outcomes. Intravenous immunoglobulins (IVIG) have also demonstrated potential benefit for refractory cases with advanced skin fibrosis.<\/jats:p>\n            <jats:p>Moreover, emerging approaches such as autologous hematopoietic stem cell transplant (AHSCT) have been evaluated in clinical trials, with evidence suggesting its ability to reset the immune system and achieve remission in skin involvement in severe cases. Chimeric antigen receptor (CAR) T cell therapy is the most recent potential pathway to target refractory skin and systemic disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Management of cutaneous involvement in SSc remains challenging. The following study provides a comprehensive review of the most recent updates in treating cutaneous aspects (and associated complications) of SSc to help clinicians establish a more effective approach managing this condition.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001082","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T12:01:44Z","timestamp":1741003304000},"page":"167-175","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies"],"prefix":"10.1097","volume":"37","author":[{"given":"Rocio","family":"Bautista Sanchez","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Khader","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine"},{"name":"University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"R1-20250326","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"R2-20250326","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1172\/JCI131700","article-title":"Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis","volume":"130","author":"Maehara","year":"2020","journal-title":"J Clin Invest"},{"key":"R3-20250326","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41467-023-44645-6","article-title":"Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis","volume":"15","author":"Ma","year":"2024","journal-title":"Nat Commun"},{"key":"R4-20250326","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","article-title":"Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R5-20250326","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/BOR.0000000000000835","article-title":"Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications","volume":"33","author":"Lescoat","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"R6-20250326","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic sclerosis-specific antibodies: novel and classical biomarkers","volume":"64","author":"Cavazzana","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"R7-20250326","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S2665-9913(23)00212-6","article-title":"Beyond very early systemic sclerosis: deciphering prescleroderma and its trajectories to open new avenues for preventive medicine","volume":"5","author":"Lescoat","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"R8-20250326","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/01.bor.0000138677.88694.a4","article-title":"Raynaud phenomenon and the vascular disease in scleroderma","volume":"16","author":"Kahaleh","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"R9-20250326","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s13760-018-1048-z","article-title":"Neurological and electroneurography findings in patients with systemic sclerosis and symptoms of neuropathic pain in extremities","volume":"121","author":"Ostojic","year":"2021","journal-title":"Acta Neurol Belg"},{"key":"R10-20250326","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/idoj.IDOJ_284_19","article-title":"Update on management of morphea (localized scleroderma) in children","volume":"11","author":"George","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"R11-20250326","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/phpp.12786","article-title":"Clinical and laboratory characterization of patients with localized scleroderma and response to UVA-1 phototherapy: in vivo and in vitro skin models","volume":"38","author":"Tognetti","year":"2022","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"R12-20250326","doi-asserted-by":"crossref","first-page":"109764","DOI":"10.1016\/j.intimp.2023.109764","article-title":"UVA1 irradiation attenuates collagen production via Ficz\/AhR\/MAPK signaling activation in scleroderma","volume":"116","author":"Shi","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R13-20250326","first-page":"4280","article-title":"UVA1 a promising approach for scleroderma","volume":"9","author":"Keyal","year":"2017","journal-title":"Am J Transl Res"},{"key":"R14-20250326","doi-asserted-by":"crossref","first-page":"757","DOI":"10.5114\/ada.2021.108437","article-title":"Effectiveness of PUVA vs. UVA1 phototherapy in the treatment of morphea patients","volume":"39","author":"Malewska-Wo\u017aniak","year":"2022","journal-title":"Postepy Dermatol Alergol"},{"key":"R15-20250326","doi-asserted-by":"crossref","first-page":"8133","DOI":"10.3390\/ijerph19138133","article-title":"Fractional ablative carbon dioxide lasers for the treatment of morphea: a case series and literature review","volume":"19","author":"Klimek","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R16-20250326","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s10103-016-2041-5","article-title":"Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma: a clinical and immunohistochemical randomized controlled study","volume":"31","author":"Shalaby","year":"2016","journal-title":"Lasers Med Sci"},{"key":"R17-20250326","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3390\/pharmaceutics14112261","article-title":"Efficacy and safety of ablative fractional laser-assisted delivery of methotrexate in adults with localized scleroderma: a randomized and controlled clinical trial","volume":"14","author":"Guo","year":"2022","journal-title":"Pharmaceutics"},{"key":"R18-20250326","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/14764172.2024.2313472","article-title":"Efficacy, tolerance and acceptability of pulsed dye laser on facial and neckline telangiectasias in systemic scleroderma: a prospective open-label monocentric study in 21 patients","volume":"25","author":"Kottler","year":"2023","journal-title":"J Cosmet Laser Ther"},{"key":"R19-20250326","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R20-20250326","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-021-02548-1","article-title":"Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort","volume":"23","author":"Jaafar","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"R21-20250326","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3390\/medicina60071024","article-title":"An overview of methotrexate indications in skin diseases","volume":"60","author":"Mocanu","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"R22-20250326","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.2011.00839.x","article-title":"The use of methotrexate in dermatology: a review","volume":"53","author":"Shen","year":"2012","journal-title":"Australas J Dermatol"},{"key":"R23-20250326","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R24-20250326","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24\u200aweek randomized double-blind trial, followed by a 24\u200aweek observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"R25-20250326","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.42510","article-title":"Efficacy and safety of lenabasum, a cannabinoid Type 2 receptor agonist, in a phase 3 randomized trial in diffuse cutaneous systemic sclerosis","volume":"75","author":"Spiera","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R26-20250326","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2478\/rir-2024-0022","article-title":"Systemic sclerosis-associated interstitial lung disease: how to manage in 2024?","volume":"5","author":"Bautista-Sanchez","year":"2024","journal-title":"Rheumatol Immunol Res"},{"key":"R27-20250326","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R28-20250326","doi-asserted-by":"crossref","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"R29-20250326","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R30-20250326","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R31-20250326","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2665-9913(22)00131-X","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial","volume":"4","author":"Ebata","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R32-20250326","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"R33-20250326","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R34-20250326","doi-asserted-by":"crossref","first-page":"15102","DOI":"10.1038\/s41598-023-42464-9","article-title":"Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis","volume":"13","author":"Speca","year":"2023","journal-title":"Sci Rep"},{"issue":"(2 Suppl 76)","key":"R35-20250326","first-page":"151","article-title":"A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis","volume":"31","author":"Takehara","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"R36-20250326","doi-asserted-by":"crossref","first-page":"103441","DOI":"10.1016\/j.autrev.2023.103441","article-title":"Immunoglobulins in systemic sclerosis management. A large multicenter experience","volume":"22","author":"Tandaipan","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R37-20250326","doi-asserted-by":"crossref","first-page":"152471","DOI":"10.1016\/j.semarthrit.2024.152471","article-title":"Role of intravenous immunoglobulins in systemic sclerosis (SSc): a systematic literature review","volume":"68","author":"Koczanowski","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R38-20250326","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous nonmyeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"R39-20250326","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"R40-20250326","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJMoa1703327","article-title":"Autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"R41-20250326","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12016-021-08891-0","article-title":"Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies","volume":"64","author":"Lescoat","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"R42-20250326","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"R43-20250326","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"R44-20250326","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/1744666X.2024.2402494","article-title":"Innovative cell therapies for systemic sclerosis: available evidence and new perspectives","volume":"21","author":"Lescoat","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"R45-20250326","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3899\/jrheum.180093","article-title":"Predictors of hand contracture in early systemic sclerosis and the effect on function: a prospective study of the GENISOS cohort","volume":"46","author":"Buni","year":"2019","journal-title":"J Rheumatol"},{"key":"R46-20250326","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/acr.23522","article-title":"Occupational therapy treatment to improve upper extremity function in individuals with early systemic sclerosis: a pilot study","volume":"70","author":"Murphy","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R47-20250326","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/ard-2023-224416","article-title":"EULAR recommendations for the nonpharmacological management of systemic lupus erythematosus and systemic sclerosis","volume":"83","author":"Parodis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R48-20250326","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00784-003-0216-5","article-title":"Effects of a nonsurgical exercise program on the decreased mouth opening in patients with systemic scleroderma","volume":"7","author":"Pizzo","year":"2003","journal-title":"Clin Oral Investig"},{"key":"R49-20250326","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4103\/JCAS.JCAS_29_21","article-title":"Efficacy of fractional CO(2) laser for improvement of limited mouth opening in systemic sclerosis","volume":"15","author":"Bhat","year":"2022","journal-title":"J Cutan Aesthet Surg"},{"key":"R50-20250326","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3727\/096368914X674062","article-title":"Autologous fat grafting in the treatment of fibrotic perioral changes in patients with systemic sclerosis","volume":"24","author":"Del Papa","year":"2015","journal-title":"Cell Transplant"},{"key":"R51-20250326","doi-asserted-by":"crossref","first-page":"e236663","DOI":"10.1136\/bcr-2020-236663","article-title":"Oro-facial fibrosis in systemic sclerosis: a reconstructive journey","volume":"13","author":"Jeon","year":"2020","journal-title":"BMJ Case Rep"},{"key":"R52-20250326","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jamadermatol.2023.3893","article-title":"Hyaluronidase injections for oral microstomia in systemic sclerosis and mixed connective tissue disease","volume":"159","author":"Min","year":"2023","journal-title":"JAMA Dermatol"},{"key":"R53-20250326","doi-asserted-by":"crossref","first-page":"43","DOI":"10.12703\/r\/10-43","article-title":"Emerging treatments for scleroderma\/systemic sclerosis","volume":"10","author":"Zhu","year":"2021","journal-title":"Fac Rev"},{"key":"R54-20250326","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/DSS.0000000000003729","article-title":"Limited systemic sclerosis-associated calcinosis cutis of the fingers treated successfully with ablative continuous-wave carbon dioxide laser and curettage","volume":"49","author":"McTighe","year":"2023","journal-title":"Dermatol Surg"},{"key":"R55-20250326","doi-asserted-by":"crossref","first-page":"152431","DOI":"10.1016\/j.semarthrit.2024.152431","article-title":"Calcinosis in systemic sclerosis: an update on pathogenesis, related complications, and management: a heavy burden still waiting to be lifted off patients\u2019 hands","volume":"66","author":"Avanoglu-Guler","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R56-20250326","first-page":"CD000467","article-title":"Calcium channel blockers for primary and secondary Raynaud's phenomenon","volume":"12","author":"Rirash","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R57-20250326","doi-asserted-by":"crossref","first-page":"128","DOI":"10.63032\/YHBL8967","article-title":"Systematic literature review to inform the Portuguese recommendations for the management of Raynaud's phenomenon and digital ulcers in systemic sclerosis and other connective tissue diseases","volume":"3","author":"Costa","year":"2024","journal-title":"ARP Rheumatol"},{"key":"R58-20250326","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s10067-023-06511-0","article-title":"Treatment of digital ulcers in systemic sclerosis: recent developments and future perspectives","volume":"42","author":"Sagonas","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R59-20250326","first-page":"235","article-title":"Practical management of Raynaud's phenomenon - a primer for practicing physicians","volume":"34","author":"Ramahi","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"R60-20250326","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5758\/vsi.240047","article-title":"Raynaud's phenomenon: a current update on pathogenesis, diagnostic workup, and treatment","volume":"40","author":"Ture","year":"2024","journal-title":"Vasc Specialist Int"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T19:45:06Z","timestamp":1743277506000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001082","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]}}}